Number:

Expires:

response...

Estimated average burden hours per

January 31,

2005

0.5

#### Emergent BioSolutions Inc. Form 3 November 14, 2006 FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0104

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| 1. Name and Address of Repo<br>Å Kramer Robert              | rting Person                              | 2. Date of Event<br>Requiring Statement<br>(Month/Day/Year)  |                                    | ne <b>and</b> Ticker<br>BioSolution  |                           |                            |   |
|---|---|--|------------------------------------|--|---------------------------|----------------------------|---|
| (Last) (First)  | (Middle)                                  | 11/14/2006   | 4. Relationsh<br>Person(s) to      | nip of Reportin<br>Issuer  | g                         | 5. If Ameno<br>Filed(Month | lment, Date Original<br>//Day/Year)                                       |
| 300 PROFESSIONAL D  | RIVE                                      |  | (Check                             | c all applicable   | )                         |                            | al or Joint/Group   |
| GAITHERSBURG, M   | DÂ 20879                                  |  | <i>v</i>                           |  | low)                      | _X_ Form fil<br>Person     | k Applicable Line)<br>led by One Reporting<br>ed by More than One<br>rson |
| (City) (State)  | (Zip)                                     | Table I -  | Non-Deriva                         | tive Securit   | ies Be                    | eneficially                | Owned   |
| 1.Title of Security<br>(Instr. 4)                           |   | 2. Amount o<br>Beneficially<br>(Instr. 4)  |                                    | 3.<br>Ownership<br>Form:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 5) | 4. Nat<br>Owne<br>(Instr. | -                          | ct Beneficial   |
| Common Stock  |   | 4,065,043  | (1)                                | Ι  | By B                      | ioPharm, I                 | L.L.C.  |
| Reminder: Report on a separat owned directly or indirectly. | e line for eac                            | h class of securities benefic  | ially S                            | EC 1473 (7-02  | )                         |                            |   |
| informa<br>require<br>current                               | tion contai<br>d to respon<br>ly valid OM | ond to the collection of<br>ned in this form are not<br>d unless the form displ<br>B control number.<br>ties Beneficially Owned ( <i>e</i> | t<br>lays a                        | warrants, opt  | tions, c                  | onvertible se              | ecurities)  |
| 1. Title of Derivative Security (Instr. 4)                  | 2. Date Ex<br>Expiration                  |  | e and Amount o<br>ities Underlying |  |                           | 5.<br>Ownership            | <ol> <li>Nature of Indirect<br/>Beneficial</li> </ol>                     |

| of Derivative Security | 2. Date Exerci      | sable and          | 5. The and Amount of                         |                        | 4.          | 5.          | 0. Nature of mullect |
|------------------------|---------------------|--------------------|--|------------------------|-------------|-------------|----------------------|
| ł)                     | <b>.</b>            |                    | Securities Underlying<br>Derivative Security |                        | Conversion  | Ownership   | Beneficial           |
|                        |                     |                    |  |                        | or Exercise | Form of     | Ownership            |
|                        |                     |                    | (Instr. 4)                                   |                        | Price of    | Derivative  | (Instr. 5)           |
|                        | Date<br>Exercisable | Expiration<br>Date | Title  | Amount or<br>Number of | Derivative  | Security:   |                      |
|                        |                     |                    |  |                        | Security    | Direct (D)  |                      |
|                        |                     |                    |  |                        |             | or Indirect |                      |
|                        |                     |                    |  |                        |             |             |                      |

## Edgar Filing: Emergent BioSolutions Inc. - Form 3

|   |             |            |                            | Shares  |        | (I)<br>(Instr. 5) |   |
|---|-------------|------------|----------------------------|---------|--------|-------------------|---|
| Employee Stock Option<br>(right to buy) | 06/30/2004  | 06/30/2007 | Class B<br>Common<br>Stock | 467,528 | \$ 0.1 | D                 | Â |
| Employee Stock Option<br>(right to buy) | (2)         | 05/25/2010 | Class B<br>Common<br>Stock | 43,588  | \$ 3.5 | D                 | Â |
| Employee Stock Option<br>(right to buy) | ( <u>3)</u> | 05/25/2010 | Class B<br>Common<br>Stock | 71,495  | \$ 3.5 | D                 | Â |

# **Reporting Owners**

\*\*Signature of Reporting Person

| <b>Reporting Owner Name / Address</b>                             | Relationships |           |                      |       |  |  |
|---|---------------|-----------|----------------------|-------|--|--|
|   | Director      | 10% Owner | Officer              | Other |  |  |
| Kramer Robert<br>300 PROFESSIONAL DRIVE<br>GAITHERSBURG, MD 20879 | Â             | Â         | President & CEO EBOL | Â     |  |  |
| Signatures  |               |           |                      |       |  |  |
| /s/Daniel Abdun-Nabi, attorney in fact                            | 1             | 1/14/2006 |                      |       |  |  |

Date

**Explanation of Responses:** 

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

An entity named "RKRAMER, L.L.C." which is wholly owned by Mr. Kramer holds 21.01% (296,875 units) of the equity interest in
 BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 4,065,043 shares of Common Stock. Mr. Kramer disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 854,139 shares.

- (2) The option is vested with respect to 17,435 shares of Class B Common Stock covered thereby and will vest with respect to the remaining shares as follows: 13,076 shares on December 31, 2006 and 13,077 shares on December 31, 2007.
- (3) The option is vested with respect to 28,598 shares of Class B Common Stock covered thereby and will vest with respect to the remaining shares as follows: 21,448 shares on December 31, 2006 and 21,449 shares on December 31, 2007.

### Â

Remarks:

Exhibit List:

## Exhibit 24-Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.